by John Conrad | Jun 28, 2024 | NewsBrief
AbbVie continues to bolster its immunology portfolio beyond Humira, announcing on Thursday its acquisition of early-stage biotech Celsius Therapeutics for $250 million in cash. This move aims to strengthen AbbVie’s longer-term prospects in inflammatory bowel...
by John Conrad | Jun 28, 2024 | NewsBrief
Meitheal Pharmaceuticals, a Chicago-based biopharmaceutical company, has made a significant move in the biosimilars market by acquiring exclusive U.S. commercial rights to YUSIMRY® (adalimumab-aqvh), a biosimilar of the widely-used drug Humira®. This strategic...
by John Conrad | Jun 27, 2024 | NewsBrief
Tempus AI, Inc. (NASDAQ: TEM) has achieved a significant milestone in the field of artificial intelligence and precision medicine. The company recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative...
by John Conrad | Jun 27, 2024 | NewsBrief
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Epkinly (epcoritamab-bysp), a joint development by AbbVie and Genmab, for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL). This approval specifically...
by John Conrad | Jun 25, 2024 | NewsBrief
In a significant advancement for heart failure treatment, Endotronix, Inc. has announced FDA Premarket Approval for their Cordella™ Pulmonary Artery (PA) Sensor System. This innovative technology promises to revolutionize the way we manage heart failure patients,...
by John Conrad | Jun 17, 2024 | NewsBrief
John Flavin, CEO of Portal Innovations, recently appeared on CNBC’s Fast Money to discuss GLP-1 drugs, early-stage biotech investing, and Portal’s unique investment model. On the topic of GLP-1 drugs for obesity and diabetes, Flavin noted that while there...
